Navigation Links
Insulet Reports Third Quarter 2008 Results
Date:11/6/2008

as anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks associated with the Company's dependence on the OmniPod System; Insulet's ability to achieve and maintain market acceptance of the OmniPod System; potential manufacturing problems, including damage, destruction or loss of any of Insulet's automated assembly units or difficulties in implementing its automated manufacturing strategy; potential problems with sole source or other third-party suppliers on which Insulet is dependent; Insulet's ability to obtain favorable reimbursement from third-party payors for the OmniPod System and potential adverse changes in reimbursement rates or policies relating to the OmniPod; potential adverse effects resulting from competition with competitors; technological innovations adversely affecting the Company's business; the Company's ability to integrate Dexcom's technology into its product; potential termination of Insulet's license to incorporate a blood glucose meter into the OmniPod System; Insulet's ability to protect its intellectual property and other proprietary rights; conflicts with the intellectual property of third parties; adverse regulatory or legal actions relating to the OmniPod System; the potential violation of federal or state laws prohibiting "kickbacks" and false and fraudulent claims or adverse affects of challenges to or investigations into Insulet's practices under these laws; product liability lawsuits that may be brought against Insulet; unfavorable results of clinical studies relating to the OmniPod System or the products of Insulet's competitors; potential future publication of articles or announcement of positions by physician associations or other orga
'/>"/>
SOURCE Insulet Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Insulet Awarded National Accreditation for Excellence by Community Health Accreditation Program
2. Insulet Corporation Announces Pricing of Secondary Public Offering
3. Insulet Corporation to Report Third Quarter 2007 Financial Results on Wednesday, November 14th
4. Insulet Corporation to Present at the JPMorgan Healthcare Conference on January 8, 2008
5. Insulet Corporation and DexCom Announce Development Agreement
6. Insulet Corporation to Present at the Seventh Annual JMP Securities Research Conference on May 20, 2008
7. Insulet Corporation to Present at the Canaccord Adams Diabetes & Obesity Conference on June 6, 2008
8. Insulet Announces Development Agreement for the First Non-Diabetes Drug Delivery Application for the OmniPod System
9. Insulet Corporation Announces Private Offering of $65 Million of Convertible Senior Notes
10. Insulet Corporation Announces Pricing of $75 Million of Convertible Senior Notes
11. Insulet Corporation to Present at the William Blair & Company 28th Annual Growth Stock Conference on June 19, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... Thanks to a $7.5 million grant from ... institutions, including American University, will operate in a new ... behavioral research aimed at ending the AIDS epidemic. , ... HIV or AIDS, according to the latest statistics. At ... over the age of 13 was living with HIV, ...
(Date:4/27/2015)... April 27, 2015 Guided by the ... of patient experience and its collaboration with organizations around ... Beryl Institute identifies eight essential actions for ... Beryl Institute believes organizations and systems committed to providing ... Identify and support accountable leadership with committed time and ...
(Date:4/27/2015)... A' Design Award and Competition is pleased to ... Boombang Inc Design Team has been announced as a ... Instruments, Medical Devices and Research Equipment Design Competition ... Inc Design Team, the creative team behind the awarded ... Lumica is a two-way communication device between patients and ...
(Date:4/27/2015)... Chicago and its seven surrounding counties have more ... communities healthier, more sustainable and more beautiful. Yet Chicago-area ... parkway trees likely to soon be destroyed by the ... “tipping point,” Chicago-area residents are concerned, as evidenced by ... . The Lisle, Illinois-based tree-focused institution’s Talking Trees survey ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Volpara ... 3.1 here at the Society of Breast Imaging’s ... 25-28, 2015 (SBI Booth #214). VolparaDensity, the ... use with digital breast tomosynthesis datasets from multiple ... the United States and worldwide. , ...
Breaking Medicine News(10 mins):Health News:D.C. Center for AIDS Research Established with New Grant from NIH 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 3Health News:Guiding Principles for Patient Experience Excellence Identified by The Beryl Institute 2Health News:Boombang Inc Design Team wins Platinum in A' Medical Product Design Awards 2Health News:New Study from The Morton Arboretum Reveals Chicagoans' Take on Trees 2Health News:New Study from The Morton Arboretum Reveals Chicagoans' Take on Trees 3Health News:New Study from The Morton Arboretum Reveals Chicagoans' Take on Trees 4Health News:Volpara Solutions Releases VolparaDensity 3.1 for Use with Tomosynthesis Systems from Multiple Manufacturers at SBI 2Health News:Volpara Solutions Releases VolparaDensity 3.1 for Use with Tomosynthesis Systems from Multiple Manufacturers at SBI 3
... claims that women who work nightshifts are more prone to ... women who regularly worked during the nights for up to ... than those who did not work at night. ,And the ... for more than three years. ,The results of ...
... Food and Drug Administration (FDA) has approved a contraceptive skin ... Johnson & Johnson, is a one-and-three-quarter-inch patch containing the hormones ... birth control pills. // ,The patch delivers the ... can be worn on the lower abdomen, buttocks or upper ...
... Inc. said it has received approval from the US ... agent Viread (tenofovir disoproxil fumarate) for the treatment of ... Viread, such drugs work by blocking the process needed ... the first nucleotide analogue reverse transcriptase inhibitor to be ...
... a group of older people in order to show- how eating ... group of 300 people aged 60 or over living in many ... or dark-skinned, those who ate lots of green leafy vegetables, beans, ... Eating less butter, red meat and sugar was also linked to ...
... according to Japanese research. ,It is thought that an ... the hardening of the arteries which could lessen blood ... there are other factors linked to moderate alcohol consumption ... researchers, at the National Institute for Longevity Sciences in ...
... of mouthwash is being hailed as a new weapon against ... some deodorants, seems to be able to prevent the growth ... of mosquitoes which causes as many as 3.2m deaths worldwide ... the agent has yet to be fully developed, the increasing ...
Cached Medicine News:
(Date:4/27/2015)... -- Bronstein, Gewirtz & Grossman, LLC is investigating potential ... Celladon Corporation ("Celladon" or the "Company") (NasdaqGM: CLDN -News).  ... or his investor relations coordinator Eitan Kimelman ... The investigation concerns whether Celladon and certain of its ... of the Securities Exchange Act of 1934.  ...
(Date:4/27/2015)... , April 27, 2015 Kalorama Information ... medical records (EMR) to grow well past the ... providers, according to a recent report.  The healthcare ... sales and continued efficiency improvements will grow the ... the next five years.  The market for EMR ...
(Date:4/27/2015)... BRH Medical, Ltd., today announced that it ... (510k) with the US Food and Drug Administration (FDA) ... feedback from the FDA during the next quarter and ... pre-market clearance. Additional pre-market regulatory filings are anticipated during ... BRH Medical, commented, "We are thrilled to have reached ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2Kalorama: EMR Market Expected To Grow Beyond Incentives 2Kalorama: EMR Market Expected To Grow Beyond Incentives 3BRH Medical, Ltd., Announces Filing of a Pre-Market Submission with the US Food and Drug Administration (FDA) for the BRH-A2 Tissue Management System 2
... WASHINGTON, Nov. 2 The owner and operator of ... guilty to defrauding the Medicare program, announced Assistant Attorney ... Attorney Tim Johnson of the Southern District of Texas ... of Health & Human Services (HHS). , Noel Wayne ...
... , BOSTON, Nov. 2 Schering-Plough Corporation (NYSE: ... ongoing Phase IIa study of narlaprevir (SCH 900518), its ... treatment-naive patients with chronic hepatitis C virus (HCV) genotype ... in which patients received a 4-week lead-in of PEGINTRON(R) ...
Cached Medicine Technology:Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 2Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 3Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 2Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 3Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 4Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 5Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 6Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 7Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 8
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... aspiration holes and additional electrode tip ... precise dissection with decreased risk of ... ,Flexible design options allow the ... and multiple tip designs. Optimize specific ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: